You are here

Open Label Extension Study of Bifeprunox

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Little Rock, Arkansas, 72201 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-66 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Outpatients who have successfully completed Wyeth study 3168A1-311-US.

2. A signed and dated informed consent form for this study.

3. No major protocol violations in previous study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Clinically important abnormalities noted in preceding short-term study that have not
resolved.

2. Use of prohibited treatments in the preceding short-term study.

3. Meeting any exclusion criteria for the preceding short-term study.

NCT00366171
Pfizer
Completed
Open Label Extension Study of Bifeprunox

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now